Evidence map›Paper›PMID 38343890›Full record

ArticleFrontiers in cellular and infection microbiology2024

The

Xabier Guruceaga, Uxue Perez-Cuesta, Adela Martin-Vicente, Eduardo Pelegri-Martinez, Harrison I Thorn, Saioa Cendon-Sanchez, Jinhong Xie, Ashley V Nywening, Andoni Ramirez-Garcia, Jarrod R Fortwendel and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Oxidoreductase geneMicrobiology spectrum · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Xabier GuruceagaDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Uxue Perez-CuestaDepartment of Immunology, Microbiology, and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
Adela Martin-VicenteDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Eduardo Pelegri-MartinezDepartment of Immunology, Microbiology, and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
Harrison I ThornDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Saioa Cendon-SanchezDepartment of Immunology, Microbiology, and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
Jinhong XieDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Ashley V NyweningDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Andoni Ramirez-GarciaDepartment of Immunology, Microbiology, and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
Jarrod R FortwendelDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States.
Aitor RementeriaDepartment of Immunology, Microbiology, and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
University of Tennessee Health Science Center · USUniversity of the Basque Country · ES

Funding

Non-cyp51A-mutation Mediated Triazole Resistance in Aspergillus fumigatusR01AI143197 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI FORTWENDEL, JARROD R., ROGERS, P. DAVID · 2020 to 2024
$3.3M
Unlocking the cidal activity of echinocandins against Aspergillus fumigatusR01AI158442 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI FORTWENDEL, JARROD R. · 2021 to 2025
$2.3M
NIAID NIH HHS R01 AI143197NIAID NIH HHS R01 AI158442
6 · The paper itself

Abstract

In this study, two distinct

Indexed as

Aspergillus fumigatusFungal ProteinsAnimalsCell Wallcis-trans-IsomerasesHomeostasisHumansMiceVirulencecis-trans-IsomerasesFungal Proteinsmaleylacetone isomeraseAspergillus fumigatuscell wallmaiAmicroarrayvirulence

Identifiers

PMID38343890
PMCPMC10853476
OpenAlexW4391261833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.